Limits that matter
A slightly clearer recording is not new eyesight.
If you are hoping for a clearer newspaper, or a face across the room, these papers are smaller than that hope. The groups were 100, 93, and 29 people. Some of the work had no placebo. A better electrical recording is not yet everyday sight, and larger independent repeats are still limited.
Macular degeneration is the main condition in this research. The American Academy of Ophthalmology has called that evidence very limited, and that note is older than the crossover. The vision page keeps the citation. These papers do not say saffron treats, cures, or replaces standard care for macular degeneration, or for any other eye condition.
Glaucoma is one small pilot, beside the drops.
One randomized pilot followed 34 people with stable open-angle glaucoma who were already using timolol and dorzolamide drops. For one month, 17 took 30 milligrams a day of an aqueous saffron extract and 17 took a placebo, on top of those drops. Eye pressure was lower in the saffron group after three weeks, and still lower at four weeks. After a month off the capsules, the two groups were no longer clearly apart. No one in that short study reported a side effect. The drops were never stopped. A month in 34 people is not a new plan for glaucoma.
PubMed 25319729
Diabetic maculopathy was a crocin tablet, not the macular capsule.
One placebo-controlled trial looked at 101 eyes of 60 people whose diabetic macular edema had already not responded to usual care, including laser and an injected medicine. They took a crocin tablet, a constituent of saffron, at 5 milligrams or 15 milligrams a day, or a placebo. The 15 milligram group showed a thinner central macula and a chart change compared with placebo. The 5 milligram group did not clearly separate from placebo. The authors called it a short-term finding and said a larger, longer study is still needed, including people who had not already failed usual care. That tablet is not the 20 milligram saffron dose in the macular trials.
PubMed 29550187
What the studies said about feeling unwell.
In the macular crossover, side effects were not clearly different from placebo. In the 12-month extension, no serious adverse event was tied to the saffron. The glaucoma pilot reported none during that month or the washout. Those are reports from the studies, not a promise that a capsule will agree with you. The preparations were not the same thing: about 20 milligrams of oral saffron in the macular work, 30 milligrams of an aqueous extract in the glaucoma pilot, and a 5 or 15 milligram crocin tablet in the diabetic trial. None of those is a kitchen pinch, and none is an amount this page is handing you.
The macular limits, in full